Sat Kartar Life Ltd

Sat Kartar Life Ltd maintains a strong liquidity position with a current ratio of 5.33, indicating that its current assets significantly exceed its current liabilities. The company holds INR 254.85 million in cash and equivalents, which is a substantial portion of its total assets of INR 637.39 million. The liquidity_fpt metric suggests that the company is well-positioned to meet short-term obligations without relying on external financing. In terms of profitability, the company reports a net income of INR 98.15 million on revenue of INR 1.63 billion, translating to a net margin of 6.02%. The return on equity (ROE) of 19.06% and return on assets (ROA) of 15.4% are both above the typical thresholds for the pharmaceutical industry, indicating strong returns relative to its equity and asset base. The company's revenue is concentrated in a single business segment focused on Ayurveda healthcare products, with no disclosed geographic diversification. The majority of its revenue is derived from India, and there is no indication of international operations or revenue diversification in the latest financial data. Looking ahead, the company's revenue is expected to grow, supported by its strong operating performance and product portfolio. The operating cash flow is currently negative at INR -50.70 million, but the free cash flow is positive at INR 59.32 million, suggesting that the company is generating sufficient cash from operations to fund its capital expenditures of INR -51.84 million. The risk assessment indicates that the company has low liquidity and dilution risks. There are no immediate filing-based liquidity or dilution flags, and the debt-to-equity ratio of 0.11 suggests a conservative capital structure with minimal leverage. The company's low dilution risk is further supported by the absence of any recent equity issuance or dilution-related disclosures. Recent events include the company's continued focus on Ayurveda-based wellness solutions and the expansion of its product portfolio. The company has not disclosed any major regulatory or operational challenges in its latest filings, and there are no indications of significant changes in its business strategy or market position.